Overall, AI outlines the transition from a reactive cardiology model toward a predictive, proactive, and precision-based approach in cardiovascular prevention, with a specific focus on risk stratification, early detection of subclinical disease, and identification of patients most likely to benefit from targeted interventions.
Simona Giubilato, L. Granata, S. Petrina· Giornale italiano di cardiol...· 0 citations
Zilebesiran is a first-in-class, subcutaneously administered small interfering RNA therapeutic that selectively silences angiotensinogen messenger RNA, the transcript encoding the common precursor of all angiotensin peptides and produces durable blood pressure lowering that can persist for up to 6 months after a single dose.
Jawaria, A. Noor, Yusra Zarlashat et al.· Life· 0 citations
This narrative review summarizes the molecular biology, genetics, epidemiology, pathophysiological mechanisms, and clinical relevance of Lp(a), and critically examines current and emerging therapeutic strategies aimed at reducing Lp(a)-mediated cardiovascular risk.
L. Granata, Simona Giubilato, Francesca Campanella et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
